The inactivation of HMGB1 has potential implications on immunogenic cell death events following anticancer intervention invoked by chemotherapeutic agents or radiotherapy, whereby HMGB1 released by dying cells serves as damage‐associated molecular patterns activating antigen‐presenting cells and facilitating presentation of tumour antigens 56. The gene discussed is HMGB1; the disease is neoplasm.